Abstract
Objective: Homocysteine (Hcy) levels are known to be elevated in various neurodegenerative and autoimmune diseases. This study investigates whether Hcy levels are altered in patients with anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis and explores their clinical significance. Methods: Plasma Hcy, C-reactive protein (CRP), and cerebrospinal fluid (CSF) parameters were analyzed in 45 patients with anti-NMDAR encephalitis and 179 age- and sex-matched healthy controls (HCs). Clinical severity was assessed using the modified Rankin Scale (mRS). Results: Patients exhibited significantly higher Hcy levels compared to HCs ($p < 0.001$), with male patients showing the highest concentrations. Following treatment, Hcy levels significantly decreased ($p = 0.004$), and this reduction correlated with clinical improvement as measured by mRS scores ($r = -0.534, p = 0.040$). Conclusion: Elevated plasma Hcy is a characteristic feature of anti-NMDAR encephalitis, particularly in males, and may serve as a biomarker for disease activity and treatment response.
Introduction
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a severe autoimmune disorder characterized by the production of antibodies against the GluN1 subunit of NMDA receptors. This leads to a range of neuropsychiatric symptoms, including behavioral changes, seizures, and cognitive deficits.
Homocysteine (Hcy) is a sulfur-containing amino acid that acts as an agonist for NMDA receptors. At elevated levels, it can cause excitotoxicity and blood-brain barrier disruption. While Hcy has been implicated in other neurological conditions, its role in anti-NMDAR encephalitis has not been previously established. This study aims to determine if Hcy levels correlate with the presence and progression of this specific encephalitis.
Methods
The study cohort included 45 Chinese Han patients (23 male, 22 female) diagnosed with anti-NMDAR encephalitis and 179 healthy controls. Plasma Hcy levels were measured using high-performance liquid chromatography (HPLC). Neurological disability was quantified using the modified Rankin Scale (mRS) at baseline and during a three-month follow-up for a subset of 15 patients.
Results
Baseline Elevation and Gender Differences
Patients with anti-NMDAR encephalitis demonstrated significantly higher median plasma Hcy levels (9.64 µmol/L) compared to healthy controls (8.32 µmol/L). A notable gender dimorphism was observed: male patients had significantly higher Hcy levels (median 11.80 µmol/L) than female patients (median 8.33 µmol/L). This difference may be attributed to physiological factors such as muscle mass or the protective effects of estrogen in females.
Correlation with Clinical Severity
Patients presenting with seizures had significantly higher Hcy levels than those without, suggesting that Hcy may lower the seizure threshold by overstimulating NMDA receptors. Furthermore, systemic inflammation was evident, as CRP levels were also significantly elevated in the patient group ($p = 0.005$).
Treatment Response and Recovery
In the follow-up subgroup of 15 patients, Hcy levels dropped significantly from a median of 10.73 µmol/L before treatment to 8.77 µmol/L three months post-treatment. Crucially, the degree of Hcy reduction was negatively correlated with changes in mRS scores, indicating that normalizing Hcy levels mirrors clinical recovery.
Discussion
The findings suggest that Hcy is not merely a bystander but a potential contributor to the pathogenesis of anti-NMDAR encephalitis. Its role as an NMDA receptor agonist may exacerbate the receptor dysfunction caused by autoantibodies. The correlation between Hcy reduction and clinical improvement highlights its potential utility as a longitudinal biomarker for monitoring treatment efficacy.
Limitations of this study include the relatively small sample size and the lack of data on genetic factors (like MTHFR variants) or nutritional status (Vitamin B12 and folate), which influence Hcy metabolism. Future research should investigate whether adjunctive therapies aimed at lowering Hcy could improve outcomes for these patients.
Summary updated